A gene expression study of normal and damaged cartilage in anteromedial gonarthrosis, a phenotype of osteoarthritis  by Snelling, S. et al.
Osteoarthritis and Cartilage 22 (2014) 334e343A gene expression study of normal and damaged cartilage in
anteromedial gonarthrosis, a phenotype of osteoarthritis
S. Snelling y*a, R. Rout ya, R. Davidson z, I. Clark z, A. Carr y, P.A. Hulley y, A.J. Price y
y The Botnar Research Centre, University of Oxford, UK
zBiomedical Research Unit, University of East Anglia, UKa r t i c l e i n f o
Article history:
Received 27 July 2013
Accepted 10 December 2013
Keywords:
Microarray
Signalling
Gene expression
Cartilage
Knee* Address correspondence and reprint requests
Research Centre, University of Oxford, UK.
E-mail address: sarah.snelling@ndorms.ox.ac.uk (S
a The ﬁrst two authors should be considered as joi
1063-4584  2013 Osteoarthritis Research Society In
http://dx.doi.org/10.1016/j.joca.2013.12.009
D license.s u m m a r y
Objective: To identify osteoarthritis (OA) relevant genes and pathways in damaged and undamaged
cartilage isolated from the knees of patients with anteromedial gonarthrosis (AMG) e a speciﬁc form of
knee OA.
Design: Cartilage was obtained from nine patients undergoing unicompartmental knee replacement
(UKR) for AMG. AMG provides a spatial representation of OA progression; showing a reproducible and
histologically validated pattern of cartilage destruction such that damaged and undamaged cartilage
from within the same knee can be consistently isolated and examined. Gene expression was analysed by
microarray and validated using real-time PCR.
Results: Damaged and undamaged cartilage showed distinct gene expression proﬁles. 754 genes showed
signiﬁcant up- or down-regulation (non-False discovery rate (FDR) P < 0.05) with enrichment for genes
involved in cell signalling, Extracellular Matrix (ECM) and inﬂammatory response. A number of genes
previously unreported in OA showed strongly altered expression including RARRES3, ADAMTSL2 and
DUSP10. Conﬁrmation of genes previously identiﬁed as modulated in OA was also obtained e.g., SFRP3,
MMP3 and IGF1.
Conclusions: This is the ﬁrst study to examine a common and consistent phenotype of OA to allow direct
comparison of damaged and undamaged cartilage from within the same joint compartment. We have
identiﬁed speciﬁc gene expression proﬁles in damaged and undamaged cartilage and have determined
relevant genes and pathways in OA progression. Importantly this work also highlights the necessity for
phenotypic and microanatomical characterization of cartilage in future studies of OA pathogenesis and
therapeutic development.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. Open access under CC BY-NC-NIntroduction
Knee osteoarthritis (OA) is common with more than 37% of
those aged over 60 showing radiographic disease1. Cartilage dam-
age in OA is likely to result from the aggregate effect of multiple
genetic, environmental, mechanical and cell biological factors
driving changes in gene expression2. These gene expression
changes alter chondrocyte activity and phenotype, further driving
OA progression. Studies of gene expression in OA have highlighted a
number of differentially regulated genes and pathways (e.g., Matrix
Metalloproteinases (MMPs) and tissue remodelling) providingto: S. Snelling. The Botnar
. Snelling).
nt ﬁrst authors.
ternational. Published by Elseviervaluable clues to the gross changes that differentiate OA from
normal cartilage3e9.
Gene expression analysis of human OA is limited by inter-
patient variability due to confounding factors including genetics
and drug therapy; cartilage is generally removed from an end-stage
joint and compared to normal cartilage from an individual without
OA. The site of cartilage excised is not always consistent across
patients or controls; and end-stage disease is heterogeneous in
both its phenotype and the mechanisms underlying its onset and
progression, thus key pathways and gene expression changes may
be masked or misrepresented3,5e7,9. In order to overcome the het-
erogeneity of human OA a number of animal models have been
utilized10. These rely on a known mechanism to induce disease
(e.g., destabilization of the medial meniscus) thus providing a
relatively consistent OA phenotype in terms of cause and time of
onset. These models provide important clues to the genes expres-
sion changes at different stages of OA pathogenesis4,11. HoweverLtd. Open access under CC BY-NC-ND license.
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equivalent disease phenotype in humans (i.e., acute injury and fast
progressing).
Studying gene expression in damaged and undamaged cartilage
from within the same joint compartment would be advantageous.
The most common phenotype of knee OA, Anteromedial Gonarth-
rosis (AMG) provides a spatially reproducible pattern of disease.
AMG affects up to 60% of patients presenting with knee OA and is
characterized by: full thickness cartilage loss in the anterior third of
the medial tibial plateau; partial thickness loss of the middle third;
and a macroscopically and histologically normal region in the pos-
terior third12. Thus AMG provides a spatial representation of carti-
lage degradation in OA, allowing comparison of undamaged and
damaged cartilage from microanatomically deﬁned regions [Fig. 1].
This study aims to characterize gene expression in AMG, a
deﬁned and common phenotype of OA13. Studying AMG has the
advantage of reproducible identiﬁcation and isolation of damaged
and undamaged cartilage from within the same joint. Additionally
AMG provides a consistent human phenotype of disease. Through
study of these deﬁned regions of damaged and undamaged carti-
lage we aim to identify genes and pathways that can be thera-
peutically targeted. We also aim to assess whether regional
variation in gene expression occurs across cartilage from the same
joint. This study will provide much needed insight into both AMG
pathogenesis and OA progression.
Materials and methods
Tissue collection
Patients were identiﬁed if attending our specialist centre for
unicompartmental knee replacement (UKR) for AMG. EthicalFig. 1. AMG. A. A medial tibial plateau resection specimen from a patient having Unicomp
demonstrate the areas of full thickness cartilage loss, partial thickness cartilage loss and ma
can be divided into equal thirds (T1, T2, T3). The undamaged cartilage is region N. T1-T3 aapproval was obtained to approach these patients and obtain
consent for use of their resected tissue in research (Ethics Reference
C01.071). Evidence of these patients having tricompartmental OA
made them unsuitable for both UKR and this study.
Ten medial tibial plateaus were collected (median age 64 years,
six right knees and four left knees, six females and four males).
Cartilage from damaged and undamaged regions was removed and
snap frozen for microarray analysis. A uniform and anatomically
aligned section was taken through all regions, wax embedded and
the blocks stored for conﬁrmation of cartilage phenotype using
Safranin-O. A further six patients were recruited and cartilage
collected for qPCR conﬁrmation studies.
RNA extraction and preparation
Damaged and undamaged cartilage was identiﬁed and isolated
using our previously deﬁned spatial model of AMG [Fig.1]. Cartilage
was ground in liquid nitrogen and RNA extracted using the RNeasy
lipid kit (Qiagen, Crawley, UK) according to the manufacturers in-
structions. All samples underwent on-column DNAse treatment.
RNA yield and quality was determined using an Agilent Bioanalyzer
and Nanodrop Spectrophotometer. The median RNA integrity
number (RIN) value was 7.3 (range 6.5e8.8), one patient was
excluded due to a low RIN value. Paired (damaged and undamaged)
samples were used for microarray at equal concentrations. Prior to
labelling, the samples were concentrated to 8.3 ml in a rotary
evaporator.
Microarray
Samples were prepared as per Agilent’s Two-Colour Microarray-
Based Gene Expression Analysis (Quick Amp Labelling v5.7)artmental knee arthroplasty (UKA) for AMG. The schematic on the right helps better
croscopically normal cartilage. B. Schematic representation of AMG. The damaged area
nd N were collected for microarray analysis.
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was stopped by the addition of 2 Agilent Hi-RPM hybridisation
buffer. Samples were loaded on to arrays (Aglient G2159F, Design
ID14850, 44,000 probes) and hybridised at 65C for 17 h at 10 RPM.
Slides were washed and scanned as per Agilent’s protocol.
Complementary DNA synthesis and real-time PCR
First strand cDNA synthesis was performed on 50 ng RNA using
Superscript III (Invitogen, Paisley, UK) according to the manufac-
turers protocol. qPCR for TNFRSF11B (OPG), SOX11, IGF1 and FGF18
was performed using predesigned primers (Quantitect, Qiagen,
Crawley, UK) and SYBR green (Qiagen, Crawley, UK) in a Rotor-Gene
RG-3,000 qPCR cycler (Qiagen, Crawley, UK). MMP1, MMP3 and
MMP13 expressionwas measured using Taqman primer-probes and
Taqman Master Mix (Applied Biosystems, Paisley, UK) on an
ABI7900HT.
Statistical analysis
Microarray signal normalisation was carried out using Agilent
Feature Extraction 9.5.3, which applied a global Lowess normal-
isation to remove systematic errors resulting from the ﬂuorescence
proﬁles of the two dyes. The normalised ﬂuorescence data was
analysed using GeneSpring GX10 (Agilent Technologies) to identify
differentially expressed genes. Transcripts identiﬁed as differen-
tially expressed had to show >2 fold differences in damaged
compared to undamaged cartilage in all of the nine individuals
tested. The fold change value represents average signal intensity of
damaged compared to undamaged cartilage across all nine pa-
tients. As all samples were paired, the Wilcoxon signed rank test (a
non-parametric test) was utilized to identify genes showing sig-
niﬁcant (P < 0.05) changes in expression using GeneSpring GX10.
P-values were not False discovery rate (FDR) corrected as the
microarray was utilized as a discovery tool with a more liberal gene
selection used to identify whether regulated genes belonged to
speciﬁc functional clusters.
Differentially expressed genes (fold >2, P < 0.05 not FDR cor-
rected) were taken forward for further analysis. Analysis of
enriched pathways and GO groups analysis was undertaken using
Ingenuity (Ingenuity Systems, California, USA), DAVID and Web-
gestalt (Vanderbilt, USA). miRNA target analysis was undertaken
using Webgestalt. Fisher Exact test (Ingenuity, DAVID) and hyper-
gometric test (Webgestalt) were used to calculate associated
pathways and GO groups. Benjamini-Hochberg was used to correct
for multiple testing.
For conﬁrmation qPCR analysis gene expression was assessed
using the standard curve method and normalised to 18S (measured
using the relevant qPCR chemistry). Paired samples were compared
and signiﬁcance (P < 0.05) assessed by aWilcoxon test using PASW
Statistics 18.0 (IBM, Illonois, USA).
Results
Microarray
754 genes (4% of the 19,365 measured) were differentially
expressed (>2 fold, P < 0.05 not FDR corrected) between damaged
and undamaged cartilage. In damaged cartilage 390 genes showed
decreased expression whilst 364 genes were expressed at a higher
level. Tables I and II show the top 50 up- and down-regulated genes.
A full list of regulated genes is available in Supplementary Table I. 11
genes showed >5-fold up-regulation in damaged cartilage and 61
>3-fold. The top upregulated genes included IL11, SOX11, DNER,
GFRA2 and FGF18. 38 genes showed >5-fold downregulation indamaged cartilage and 128 >3-fold. Down-regulated genes
included LAMB1, SPARCL1, SFRP4 and MMP13 Table III.
67 Gene ontology (GO) groups were enriched (P < 0.01) Table II,
Fig. 2. Regulated GO groups include those related to Extracellular
Matrix (ECM), immune systemprocess, signal transduction, collagen
metabolic process and response to wounding. Strikingly, ECM-
related GO groups were the major groups showing up-regulation
of gene expression in damaged cartilage, whilst genes from all sig-
niﬁcant GO groups showed down-regulation in damaged cartilage.
Ingenuity analysis identiﬁed three major regulated pathways
showing dysregulation between damaged and undamaged carti-
lage [Fig. 3]. These are:
1. Cellular Development, Skeletal and Muscular System Develop-
ment and function, Lymphoid tissue structure development
2. Inﬂammatory response, cell death, haematological disease
3. Skeletal and muscular disorders, cell signalling, small molecule
biochemistry
We carried out further pathway analysis using the DAVID and
Webgestalt bioinformatic tools (Supplementary Tables II-IV). These
conﬁrmed the marked alteration between damaged and undam-
aged cartilage of cell signalling, inﬂammatory and cell matrix
related pathways. Signiﬁcantly associated pathways (P < 0.05)
included ECM-receptor interactions, focal adhesion, haemato-
poietic cell lineage, TGF signalling, and MMPs. Furthermore disease
enrichment analysis identiﬁed arthritis, joint diseases, inﬂamma-
tion and rheumatoid arthritis (P < 1  10e18). microRNA target
analysis identiﬁed OA- and inﬂammation relevant miRs including
miR200, miR145 miR23a (P < 1  10e5).
Comparison with other published microarrays of human knee
OA cartilage conﬁrmed OA-related changes in expression of genes
including FN1, INHBA and TNFAIP63,7,8. However some genes
including MMP1, MMP3 and COL1A2 showed an opposite direction
of regulation compared to that previously reported3,6e8. Genes
previously not reported as regulated in OA include RARRES3,
ADAMTSL2 and DUSP1. A single study of human hip OA cartilage
vs neck of femur fracture control revealed 899 differential
expressed genes, 59 of these are also altered in our study; 34 in the
same direction (e.g., MMP1, MMP3); 25 in the opposite direction
(e.g., BMP6 and TGM2)14. COL12A1 and STAB1 are the only differ-
entially expressed genes within genetic loci marked by SNPs that
genome wide association studies have identiﬁed as key signals in
OA15e17. Comparison microarray analysis of murine and rat injury
models of OA showed quite distinct gene expression proﬁles,
however some common genes including INHBA, TNFAIP6 and TGM2
were identiﬁed4,11,18,19.
Real-time PCR
SOX11, IGF1, FGF18, MMP1, MMP3 and MMP13 were selected for
conﬁrmation ofmicroarray data. Geneswere selectedbased on their
broad spectrum of roles in cartilage biology. SOX11, a transcription
factor in embryonic development, was selected as it showed a high
fold change in gene expression (8.66 fold higher in damaged carti-
lage) yet is relatively unstudied in OA. FGF18 (4.69 higher in
damaged cartilage) IGF1 (5.10 lower in damaged cartilage), MMP1
(6.28 fold lower in damaged cartilage), MMP3 (3.19 fold lower in
damaged cartilage) and MMP13 (7.05 lower in damaged cartilage)
were selected due to their known functions in cartilage develop-
ment and homoeostasis, and to conﬁrm the direction of MMP
expression changes reported in our microarray data20e22.
TNFRSF11B (3.69higher indamagedcartilage), has previously shown
increased expression in OA cartilage but is generally regarded as a
mediator of bone rather than cartilage metabolism23,24.
Table I
The top 50 upregulated genes in damaged cartilage compared to undamaged cartilage
Gene name Gene symbol Fold P-value
Interleukin 11 IL11 15.9 0.0109
SRY (sex determining region Y)-box 11 SOX11 8.66 0.0077
Delta/notch-like EGF repeat containing DNER 8.15 0.0077
Chromosome 15 open reading frame 48 C15orf48 7.88 0.0077
Chromosome 5 open reading frame 23 C5orf23 6.98 0.0209
GDNF family receptor alpha 2 GFRA2 6.19 0.0077
Chemokine (C-X-C motif) ligand 14 CXCL14 6.17 0.0077
UDP-N-acetyl-alpha-D-galactosamine:polypeptide
N-acetylgalactosaminyltransferase-like 1
GALNTL1 5.98 0.0077
Brain and acute leukaemia, cytoplasmic BAALC 5.60 0.0077
Prostaglandin E receptor 1 (subtype EP1) PTGER1 5.04 0.0209
GDNF family receptor alpha 2 GFRA2 4.96 0.0077
Fibroblast growth factor 18 FGF18 4.68 0.0077
S100 calcium binding protein A2 S100A2 4.41 0.0077
Coagulation factor C homologue, cochlin COCH 4.33 0.0284
Chloride intracellular channel 3 CLIC3 4.23 0.0077
Transglutaminase 2 TGM2 4.10 0.0077
Chloride channel Ka CLCNKA 3.98 0.0109
KIAA1622 transcript variant 2 KIAA1622 3.93 0.0077
Glutamate receptor, ionotropic, AMPA 2 GRIA2 3.88 0.0077
Cartilage oligomeric matrix protein COMP 3.86 0.0077
Urocanase domain containing 1 UROC1 3.86 0.0152
Growth differentiation factor 6 GDF6 3.85 0.0152
Angiopoietin-like 4 ANGPTL4 3.84 0.0077
Annexin A8 ANXA8 3.81 0.0152
Ring ﬁnger protein 152 RNF152 3.77 0.0077
Cytoplasmic FMR1 interacting protein 2 CYFIP2 3.77 0.0077
Olfactory-like receptor PJCG2 OR7E13P 3.77 0.0077
Tumour necrosis factor receptor superfamily, member 11b TNFRSF11B 3.69 0.0077
Rho guanine nucleotide exchange factor (GEF) 15 ARHGEF15 3.63 0.0077
Serpin peptidase inhibitor, clade E
(nexin, plasminogen activator inhibitor type 1), member 2
SERPINE2 3.62 0.0077
GDNF family receptor alpha 2 GFRA2 3.59 0.0284
Heparan sulphate (glucosamine) 3-O-sulfotransferase 3A1 HS3ST3A1 3.52 0.0077
HtrA serine peptidase 3 HTRA3 3.48 0.0077
Progestin and adipoQ receptor family member IX PAQR9 3.45 0.0077
Laminin, beta 3 LAMB3 3.44 0.0077
LIM domain only 6 LMO6 3.43 0.0077
ADAMTS-like 2 ADAMTSL2 3.40 0.0077
BTB (POZ) domain containing 16 BTBD16 3.34 0.0077
Glucagon-like peptide 2 receptor GLP2R 3.32 0.0077
cDNA FLJ41861 ﬁs, clone NTONG2008672 C1orf170 3.27 0.0152
Follistatin-like 3 (secreted glycoprotein) FSTL3 3.24 0.0077
Syntaxin 1A (brain)] STX1A 3.23 0.0077
HtrA serine peptidase 1 HTRA1 3.23 0.0077
Laminin, gamma 3 LAMC3 3.20 0.0077
Noggin NOG 3.18 0.0077
Bone morphogenetic protein 6 BMP6 3.13 0.0109
Metallothionein 3 MT3 3.10 0.0152
Decay-accelerating factor 4ab CD55 3.10 0.0077
Syntaxin 1A STX1A 3.05 0.0077
Cytokine receptor-like factor 1 CRLF1 3.04 0.0109
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SOX11: 6.7 fold higher in damaged cartilage (P ¼ 0.043), IGF1: 5.2
fold lower in damaged (P ¼ 0.043), TNFRSF11B: 6.9 fold higher in
damaged (P ¼ 0.043), MMP1: 1.88 lower in damaged (P ¼ 0.046)
MMP3: 3.68 fold lower in damaged (P ¼ 0.031), MMP13: 4.62 fold
lower in damaged (P ¼ 0.028) [Fig. 4]. These expression changes
conﬁrmed the direction of gene expression changes detected in our
microarray analysis. There was no signiﬁcant difference in FGF18
expression (P ¼ 0.08) although the pattern of expression suggested
an increase in damaged cartilage and expression differences were
seen with immunohistochemistry (data not shown).
Discussion
This study is the ﬁrst to detail gene expression changes between
undamaged and damaged cartilage taken from the same jointcompartment of individuals with a common and speciﬁc pheno-
type of OA (AMG). The pattern of cartilage damage in AMG is
reproducible across individuals. We show clear gene expression
differences between damaged and undamaged cartilage and pro-
vides important clues to dysregulated pathways in OA. This study
highlights the complexity of the OA joint and the variation in gene
expression phenotype of chondrocytes from different locations
within the same joint. Thus our study emphasizes the requirement
to understand the behaviour of different cartilage regions in order
to successfully study OA and target therapeutics.
We have identiﬁed changes in ECM, immune system processes
and signal transduction between damaged and undamaged carti-
lage. Proteineprotein interaction networks related to cellular,
skeletal and muscular system development also showed signiﬁcant
gene expression changes. The identiﬁcation of immune system
process and response to wounding are particularly interesting as
Table II
The top 50 down-regulated genes in damaged cartilage compared to undamaged cartilage
Gene name Gene symbol Fold change P-value
Laminin, beta 1 LAMB1 15.3 0.0076
SPARC-like 1 SPARCL1 11.5 0.028
Basic helix-loop-helix domain containing, class B, 5 BHLHB5 9.8 0.011
Glycoprotein (transmembrane) nmb GPNMB 9.5 0.0076
Major histocompatibility complex, class II, DM beta HLA-DMB 8.7 0.015
Major histocompatibility complex, class II, DR alpha HLA-DRA 8.3 0.021
Collagen, type XIV, alpha 1 COL14A1 8.3 0.0077
Chemokine (C-X-C motif) ligand 12 CXCL12 8.0 0.038
Phosphodiesterase 1A PDE1A 7.9 0.0077
NEL-like 1 NELL1 7.7 0.021
Secreted frizzled-related protein 4 SFRP4 7.6 0.011
Matrix metallopeptidase 2 MMP2 7.2 0.0077
Allograft inﬂammatory factor 1 AIF1 7.2 0.021
Metallopeptidase 13 MMP13 7.1 0.021
Collagen, type XIV, alpha 1 COL14A1 7.0 0.015
Proprotein convertase subtilisin/kexin type 1 PCSK1 6.8 0.0077
Secreted frizzled-related protein 1 SFRP1 6.8 0.038
Interferon-induced protein 44 IFI44 6.5 0.0077
Complement component 3 C3 6.5 0.011
Plasminogen activator PLAU 6.4 0.011
Raftlin, lipid raft linker 1 RFTN1 6.4 0.0077
Matrix metallopeptidase 1 MMP1 6.3 0.011
Plexin domain containing 1 PLXDC1 6.0 0.0077
Serpin peptidase inhibitor, clade F SERPINF1 5.8 0.0077
Colony stimulating factor 1 receptor C51FR 5.8 0.0077
Cadherin 11, type 2 CDH11 5.51 0.0077
Olfactomedin-like 3 OLFML3 5.47 0.0077
Fibrinogen-like 2 FGL2 5.44 0.0152
Matrix metallopeptidase 9 MMP9 5.43 0.0077
Major histocompatibility complex, class II, DR beta 4 HLA-DRB4 5.33 0.0382
G protein-coupled receptor 124 GPR124 5.28 0.0077
Hepatitis A virus cellular receptor 2 HAVCR2 5.27 0.0077
Twist homologue 1 TWIST1 5.16 0.0077
Insulin-like growth factor 1 IGF1 5.09 0.0077
Chemokine (CeC motif) ligand 2 CCL2 5.03 0.0077
Bone marrow stromal cell antigen 2 BST2 5.03 0.0077
Family with sequence similarity 20, member A FAM20A 5.01 0.0077
Olfactomedin-like 3 OLFML3 4.98 0.0077
V-set and immunoglobulin domain containing 4 VSIG4 4.97 0.0382
Acyl-Coenzyme A oxidase 2, branched chain ACOX2 4.95 0.0077
Lymphoid enhancer-binding factor 1 LEF1 4.94 0.0077
Interleukin 13 receptor, alpha 2 IL13RA2 4.89 0.0077
Mannosidase, alpha, class 1C, member 1 MAN1C1 4.78 0.0077
Phospholipase C-like 2 PLCL2 4.70 0.0077
Leucine rich repeat containing 15 LRRC15 4.67 0.0109
Brain abundant, membrane attached signal protein 1 BASP1 4.65 0.0109
Q8SPE4_9PRIM THC2632039 4.64 0.0209
WNT1 inducible signalling pathway protein 2 WISP2 4.55 0.0077
Caspase 1 CASP1 4.54 0.0077
Acid phosphatase 5, tartrate resistant ACP5 4.53 0.0209
Chemokine (CeC motif) ligand 3 CCL3 4.49 0.0077
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relevant to OA pathogenesis25,26. Although only a small percentage
of genes show altered expression between damaged and undam-
aged cartilage these potentially have signiﬁcant biological impli-
cations on tissue activity due to their aggregate effects and impact
on chondrocyte behaviour.
Matrix degrading enzymes MMP1, MMP2, MMP3, MMP9 and
MMP13 showed higher levels of expression in undamaged cartilage.
Our study highlights that different regions of cartilage in an OA
joint may have differing catabolic and anabolic activity. The higher
expression of MMPs in undamaged cartilage adjacent to a lesion
may be an attempt to actively remodel undamaged cartilage in
response to an altered cellular environment. This in turn may
reﬂect the changes in expression of ECM components. These
expression changes may be driven by changes in weight-bearing as
a result of cartilage damage elsewhere in the joint and by inherent
loading differences due to location within the joint. Studies of hipOA show decreased MMP expression in hip OA cartilage, perhaps
suggesting a similar mechanical environment of the hip cartilage
sampled. Decreased load has been shown to increase MMP
expression in tendon, cartilage and bone cells and thus mechanical
off-loading may be driving the MMP expression changes seen in
our study27e29, interestingly, no differential Tissue inhibitor of
metalloproteinase (TIMP) expression was detected in our study.
This suggests that MMP activity may be further reduced in
damaged compared to undamaged cartilage due to greater avail-
ability of TIMP to inhibit MMP activity. Future work should assess
MMP activity across damaged and undamaged cartilage regions.
Inﬂammatory processes are known to regulate ECM production
and remodelling. Our study shows up-regulation of inﬂammatory
genes (e.g., C2, CCL2, CCL3) in undamaged cartilage as well as
alteration in MMPs and matrix genes suggesting a distinct but
necessary inﬂammatory component drives OA. Inﬂammatory me-
diators expressed in undamaged cartilage as well as bone and
Table III
Enriched GO groups showing differential expression in damaged compared to undamaged cartilage. [ ¼ upregulated in damaged cartilage, Y ¼ down-regulated in damaged
cartilage
GO Accession GO term P-value Corrected P-value Example regulated genes
GO:0005576 Extracellular region 8.12E-30 2.09E-24 [ADAMTS6 CILP FGF18 TNFRSF11B
YB2M CCL3 COL1A1
GO:0031012 Extracellular matrix 6.19E-22 5.32E-17 [ADAMTSL2 COMP FMOD LAMB3
YCHI3L1 COL1A2 FBLN1 MATN2
GO:0005578 Proteinaceous extracellular matrix 2.18E-21 1.40E-16 [FGF1 MUC2 NTN1 TGM2
YCOL12A1 CPZ MATN4 THBS2
GO:0002376 Immune system process 3.58E-14 1.85E-09 [CXCL4 TNFSF10 CD8B CRHR1
YIL4R IL18BP CCL2 FAS C2 CCL4 C1 C3 IFIT3
GO:0007155 Cell adhesion 4.55E-11 1.47E-06 [LAMC3 SDK2 VWA1 DST ADAM12 SDK1
YIBSP COL12A1 CADM1 STAB1 NID2
GO:0005615 Extracellular space 9.78E-11 2.80E-06 [CXCL14 FGF18 ANGPTL4 HTRA1
YPTN PLAU SEPP1 SPON2
GO:0007165 Signal transduction 1.89E-08 3.48E-04 [TNFAIP6 FGF1 AXIN2 WIF1
YCAMK1 NOG IGF1 FRZB SFRP1 WISP2 WNT10A
GO:0044254 Multicellular organismal protein
catabolic process
9.30E-08 0.001042428 YMMP13 MMP2 MMP9
GO:0044256 Protein digestion 9.30E-08 0.001042428 YMMP11 MMP9 MMP3
GO:0044259 Multicellular organismal macromolecule
metabolic process
9.30E-08 0.001042428 YMMP 1 MMP19 MMP11
GO:0032963 Collagen metabolic process 9.30E-08 0.001042428 YMMP1 MMP2 MMP3
GO:0030574 Collagen catabolic process 9.30E-08 0.001042428 [PRSS2 ASCL5
YMMP 9 MMP11 MMP13
GO009611 Response to wounding 2.81E-07 0.002584188 [FN1
YTLR4 CFHR1 LY96 C4BPA CX3CR1 PTX3
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regions. The lower expression of inﬂammatory genes in damaged
regions may also indicate a completely dysregulated responsive-
ness in this highly degraded cartilage where chondrocytes previ-
ously in deep zones are now exposed to the biochemical milieu of
the joint.Fig. 2. Distribution of up- and down-regulated genes within enriched GO groups.
Differentially expressed genes were classiﬁed according to their GO group. GO groups
that were signiﬁcantly enriched were selected and the number of genes within each
group that were up- or down-regulated in damaged compared to undamaged cartilage
was calculated. Genes were included if there expression was showed >2 fold change in
expression in all nine individuals with P < 0.05. Unﬁlled bars represent genes that
were expressed at a higher level y in damaged compared to undamaged cartilage.
Shaded bars represent those expressed at a lower level in damaged compared to
undamaged cartilage. ECR ¼ Extracellular Region. ECM ¼ Extracellular Matrix.Genes down-regulated in damaged cartilage include members
of the complement system e.g., C2 and C4BPA. The membrane
attack arm of the complement pathway has previously been re-
ported to be involved in OA30. In support of this, the relative up-
regulation of complement in undamaged cartilage in AMG may act
to provide low-level complement activation and contribute to OA
pathogenesis.
Our study also supports the hypothesis that disrupted chon-
drocyte signal transduction is a key modulator of OA pathogenesis.
The Bone Morphogenetic Protein (BMP) andWnt pathways are key
for development and homoeostasis of cartilage and showed sig-
niﬁcant alterations in gene expression between damaged and un-
damaged cartilage.
A number of BMP antagonists show differential expression
including NOG, FSTL3 CHRDL2 and BMPER. NOG is expressed in
articular cartilage, is required for articular joint formation, and
NOG  mice are protected from inﬂammation-drive joint destruc-
tion31,32. FSTL3 is an inhibitor of Activin signalling and knockout
mice show severe articular cartilage lesions when compared to
wild-type controls33. CHRDL2 is increased in the midzone of OA
cartilage and can inhibit chondrocyte mineralization34. BMPER can
antagonize BMP-induced chondrogenesis by ATDC5 chon-
droprogenitor cells, however it has also been reported to have pro-
BMP activity through binding to chordin35,36. Up- and down-
regulation of BMP antagonists and modulators in our study sug-
gest the balance of BMP signalling is altered in distinct cartilage
regions in OA and that Smad signalling in general is disrupted. In
support of this, HTRA1 and ADAMTSL2, antagonists of TGFb signal-
ling are increased in damaged cartilage in our study. BMP mainly
signals through Smad1/5/8 and TGFb through Smad2/3. However
TGFb-mediated Smad1/5/8 signalling is reported to become
dominant in OA with a concurrent decrease in both TGFb and
Smad2/3 signalling, Smad3 null mice also show increased OA
development37e39. In our study, INHBA, an activator of Smad2/3
signalling is upregulated in damaged cartilage, and its up-regula-
tion may suggest an attempt at reactivation of Smad2/3 signalling
in a feedback loop. Our data suggests that not only is there a po-
tential for a change in Smad2/3 and Smad1/5/8 balance in OA, but
Fig. 3. Pathway analysis. Ingenuity analysis on differentially expressed genes in damaged and undamaged cartilage revealed three proteineprotein interaction networks showing
signiﬁcant association. These were, A. Cellular Development, Skeletal and Muscular System Development and function, Lymphoid tissue structure development. B. Inﬂammatory
response, cell death, haematological disease. C. Skeletal and muscular disorders, cell signalling, small molecule biochemistry Nodes shaded grey are genes with signiﬁcant
expression differences in the microarray.
S. Snelling et al. / Osteoarthritis and Cartilage 22 (2014) 334e343340also that the ﬁne-tuning of these Smad-pathways and their in-
teractions is disrupted.
Under- and over-activation of the Wnt pathway results in OA in
transgenic mice and Wnt pathway members are regulated by
articular cartilage injury in vitro [ref] and show altered expression
in human OA40,41. The Wnt antagonist, SFRP3 is down-regulated in
damaged cartilage in our study and SFRP3 knockout mice show
increased proteoglycan loss in OA models42. Expression of a num-
ber of Wnt e inducible genes including LEF1, WISP2 and TWIST1
were decreased in damaged cartilage in our study, as was the Wnt
receptor FZD5. Furthermore FGF18, RUNX2, IGF1, FMOD, COL5A1, FN1
are also Wnt target genes showing altered expression. Our study
not only conﬁrms considerable dysregulation of Wnt signalling in
OA but also suggests dysregulation within the same joint depen-
dent on cartilage degradation status and anatomical location. The
mechanism underlying this dysregulation are unknown and may
result from biological and mechanical upstream regulators of bothWnt and TGF/BMP pathways and cross-talk between these and
other signal transduction pathways in the chondrocyte.
Other regulated genes include DUSP10, a phosphatase that
blocks MAPK activation and can protect from oxidative stress, and
PSMB9 a proteosomal component; suggesting a role for stress-
induced signalling in OA pathogenesis43,44. RARRES3 a retinoic
acid receptor showed decreased expression in damaged cartilage
and may indicate a role of retinoic acid signalling, a key develop-
mental signalling pathway, in OA.
Altered expression of signal transduction components will
markedly impact chondrocyte behaviour between damaged and
undamaged cartilage. These differences in signalling activity pose
obvious complications when targeting pathwayswith OA therapies.
Altered activities within damaged and undamaged regions could
potentially cause deleterious effects in one cartilage zone despite
positive effects in the other. This highlights the importance of
discriminating the microanatomical location and degradation
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Fig. 4. Real-time PCR analysis. RNAwas extracted from damaged and undamaged cartilage to conﬁrm expression changes seen in the microarray analysis. Real-time PCR was carried
out to assess gene expression of MMP1, MMP3, MMP13, SOX11, IGF1, FGF18 and TNFRSF11B.
S. Snelling et al. / Osteoarthritis and Cartilage 22 (2014) 334e343 341status of cartilage so that achievable therapeutic targets are iden-
tiﬁed. This can only be achieved by studying cartilage with known
damage status and location and not indiscriminately harvesting
entire joint surfaces.
Developmental- and skeletal injury-related networks also
showed altered expression between damaged and undamaged
cartilage. Regulated genes include ATF3 and TNFRSF11B. ATF3 is
upregulated during chondrocyte terminal differentiation and its
overexpression decreases SOX9 promoter activity and increases
RUNX2 expression, thus altering the direction of chondrogenic
differentiation45. TNFRSF11B (OPG) is an osteoclastogenesis inhibi-
tor and shows increased expression in damaged cartilage in our
study. The altered expression of bone-related genesmay impact not
only the chondrocytes but also the underlying subchondral bone,
and also suggests regulation of pathways more akin to endochon-
dral development. The signiﬁcant alteration in developmental gene
expression supports the hypothesis that chondrocytes in OA may
assume a more developmental phenotype as an attempt at tissue
repair.
A number of genes showing differential expression in our study
corroborate those seen in other microarray studies of human and
murine OA. However several genes show opposite changes in gene
expression. This may be accounted for by the distinct phenotype of
AMG and our comparison of speciﬁc microanatomical regions,
whilst in other reports, OA cartilage has been compared to non-OA
or early-OA samples from different individuals. Thus OA cartilage in
other studies may consist of varying proportions of damaged and
undamaged cartilage. Although predominant gene expression
changes can be captured, the proportion of each region present in
these pooled sample will impact the directionality of gene
expression changes. Additionally variation due to confounding
factors such as drug treatment are removed by comparing cartilage
fromwithin the same joint in AMG patients vs between OA patients
and controls. It is also likely that temporal changes in gene
expression occur during progression from AMG, in our study, to
end-stage tricompartmental OA, in other studies.
Only a limited number of genes were found in common when
we compared the gene expression changes in the present study
with those previously reported in the DMM murine model of OA.
This may reﬂect the different mechanisms and speed of disease
onset, time of sampling and the inclusion of whole joint or entirecartilage (both damaged and undamaged) when analysing
expression in animal studies. Genes in common include TNFAIP6
and INHBA (upregulated in OA and damaged cartilage) and may be
representative of major OA-related pathways and expression
changese as these changes are also seen in other published studies
of gene expression in human knee OA7,8.
Studies, including that by Sato et al. do compare damaged and
undamaged cartilage from within the same knee in human OA8.
Ourwork conﬁrmed the directional regulation of a number of genes
identiﬁed by Sato et al. (e.g.,. ETS1, SOX11, TNFAIP6) emphasising
that deﬁning cartilage degradation status does result in more
consistent identiﬁcation of gene expression changes in OA. The
cartilage used in the work by Sato et al. is taken from end-stage
tricompartmental OA. The early disease phenotype of these pa-
tients, and thus themechanisms underlying disease pathogenesis is
likely to be heterogenous compared to the more well-deﬁned
natural history of AMG. This may account for differences between
this and our study and may provide clues to genes involved in
driving AMG vs those driving other OA phenotypes.
It has been postulated that AMG cartilage lesions may be
exacerbated by heel strike force46 and future studies should seek to
model and integrate topographical differences in joint loading over
time with disease-mediated changes in regional gene expression.
Chondrocyte phenotype will undoubtedly be inﬂuenced by the
alteration in weight-bearing regions secondary to failing and
eroded cartilage, with changes in MMP expression in our study
potentially reﬂecting mechanical off-loading. It will also be
important to assess gene expression across microanatomical re-
gions in non-OA controls to allow further delineation, by subtrac-
tive analysis, of OA- and loading-associated genes. This will build
upon the limitations of our study and provide further under-
standing of OA pathogenesis and potential targets for therapeutic
intervention.
Through using a deﬁned phenotype of OAwe have captured and
compared a temporal and spatial stage of cartilage degeneration
and identiﬁed key genes and pathways regulated in OA. We hy-
pothesize that in AMG and in OA the signalling environment of
chondrocytes in distinct microanatomical regions is altered. This
altered signalling environment results in an altered cellular
phenotype speciﬁc to the chondrocyte location within the tibial
plateau. Chondrocytes undergo repair attempts leading to
S. Snelling et al. / Osteoarthritis and Cartilage 22 (2014) 334e343342alteration in ECM components and the attempted activation of
developmental pathways as well as the production of soluble fac-
tors such as inﬂammatory cytokines. Behaviour of chondrocytes in
distinct regions may inﬂuence, and be inﬂuenced by secreted
proteins from chondrocytes in other regions as well as underlying
subchondral bone and synovium. We have shown distinct gene
expression proﬁles between damaged and undamaged cartilage
taken from the same joint of individuals with a deﬁned and com-
mon phenotype of knee OA. This emphasises the importance of
using phenotypically and microanatomically well-deﬁned regions
of cartilage when analysing OA gene expression and chondrocyte
behaviour and when developing therapeutics.
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